

REPROS THERAPEUTICS INC.

Form 8-K

January 21, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): January 16, 2014

Repros Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware      001-15281      76-0233274

(State or Other (Commission File (I.R.S. Employer

Jurisdiction of Number)      Identification No.)

Incorporation)

2408 Timberloch Place, Suite B-7  
The Woodlands, TX 77380  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (281) 719-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ..Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- ..Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- ..Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
- ..Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 16, 2014, the Compensation Committee of the Board of Directors of Repros Therapeutics Inc. (the “Company”) approved a grant to Katherine Anderson, the Company’s Chief Financial Officer, of options to purchase 5,000 shares of the Company’s common stock, \$0.001 per share (the “Common Stock”), as compensation for her work in 2013. The options, which were granted under the Company’s 2011 Equity Incentive Plan, have a per share exercise price of \$21.48, the closing price of the Common Stock on the Nasdaq Stock Market on the date of grant, a term of 10 years, and will vest in quarterly installments over the three years following the date of grant.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**REPROS  
THERAPEUTICS INC.**

By: /s/ Katherine Anderson  
Katherine Anderson  
CFO

Dated: January 21, 2014